Description
eraCare GmbH is a German provider of diagnostic multi-gene expression tests in dermato-oncology. Its prognostic test MelaGenix supports doctors to offer efficient risk assessment and treatment decisions to patients with cutaneous malignant melanoma. In synergy with conventional histopathology (AJCC staging), the MelaGenix test allows for the precise prediction of tumor-specific survival in more than 90% of all patients presenting with primary cutaneous melanoma.
Melanoma has become more frequent worldwide; and more than 14% of melanoma patients die, because risk has not been identified in time for appropriate treatment. These patients may be saved when identified early and treated upfront.
NeraCare’s business model relies on the proprietary MelaGenix gene expression test providing the missing link between 1st diagnosis and evidence-based treatment decisions in malignant melanoma, thus allowing for precision patient care:
The MelaGenix test analyzes individual gene activity profiles in the tumor microenvironment by applying a patented algorithm. The resulting test score predicts risk of relapse and tumor-related death. MelaGenix has been independently validated, in vitro and in silico, and has an unparalleled statistically significant prognostic power. It is the only available patent-protected prognostic test that enables doctors to design, in combination with histopathology (AJCC) staging, personalized therapeutic solutions, leading to better clinical outcome, reduced side effects, higher patient satisfaction and more efficient use of health care funds in cutaneous melanoma. In contrast, mutational analyses of melanoma oncogenes cannot predict risk of relapse (prognosis) or need for adjuvant therapy, but do predict response to specific tumor therapies (“predictive biomarkers”, such as BRAF).
Tell your friends
Quiz
